• linkedin
  • Increase Font
  • Sharebar

    Active surveillance linked with moderate anxiety

    Anxiety level likely to recede with longer follow-up, research shows

    Men undergoing active surveillance for prostate cancer experienced levels of anxiety that were moderate, but that decreased over time, according to results of a large, prospective cohort study presented at the 2017 Society of Urologic Oncology annual meeting in Washington.

    These findings should be taken into consideration when counseling men on active surveillance, said first author Karim Marzouk, MD, urologic oncology fellow at Memorial Sloan Kettering Cancer Center, New York.

    “I think what we need to stress is that this entity exists—the anxiety is real—but at the same time, we just need to make sure patients and their family members are aware” that it will likely recede with longer follow-up, Dr. Marzouk said in an interview with Urology Times.

    Patients might also be reassured to know that active surveillance entails very close follow-up over time, Dr. Marzouk added.

    While acceptance of active surveillance is growing, few data exist on anxiety associated with the approach and how it might impact management decisions. Some previous studies suggest an estimated 5% to 13% of patients will terminate active surveillance and opt for treatment due to cancer-related anxiety, according to Dr. Marzouk.

    Read: PCa-specific mortality not affected by comorbidity

    Dr. Marzouk presented the study, which included 463 patients enrolled in active surveillance from March 2000 through January 2016.

    Next: Disease-specific questions asked

    Andrew Bowser
    Andrew Bowser is a medical writer based in Brooklyn, New York.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available